Alexander de Leeuw Advocaat

Alexander de Leeuw


Alexander is a lawyer at Brinkhof with expertise in complex patent litigation. He has successfully represented clients in various courts, including the District Court and Court of Appeal in The Hague, and the European Patent Office. Alexander has worked at Brinkhof since his admission to the bar, specialising in intellectual property.

(inter)national patent proceedings

Alexander specialises in national and international patent litigation, with a focus on pharmaceutical inventions, medical devices and consumer goods. He also regularly handles cases related to the protection of know-how and trade secrets, as well as advising on regulatory issues such as marketing authorisations, data and brand exclusivity, and orphan drugs.

Experience & ancillary activities

Besides litigation, Alexander enjoys publishing on the subject of patent law, in particular on developments in the field of software patents and artificial intelligence. He is a co-author of Software Patents Worldwide. Alexander also regularly contributes to AIPPI Questionnaires and gives guest lectures on patent law and the protection of trade secrets at various universities. He is an active member of AIPPI, Young EPLAW, LES and ARRIGE.

Alexander studied Law in Amsterdam (University of Amsterdam), New York (Benjamin N. Cardozo School of Law, Yeshiva University) and Copenhagen (University of Copenhagen). He also completed a postgraduate education program on health law, which provides him with a valuable perspective on regulatory issues in the pharmaceutical industry. Alexander was admitted to the Dutch bar in 2015.

Some of the cases Alexander de Leeuw has handled:

  • on behalf of the Broad Institute, defending, in opposition proceedings, an extensive patent portfolio relating to the ground-breaking CRISPR technology that enables the modification of DNA;
  • defending Alvotech in proceedings against AbbVie concerning whether applying to the EMA for market authorisation without a carve-out for a patented indication of adalimumab constitutes an unlawful act;
  • conducted preliminary relief proceedings against Cook on behalf of Boston Scientific, seeking a cross-border injunction due to patent infringement involving endoscopic devices;
  • representing Sandoz in the pan-European dispute against Eli Lilly concerning pemetrexed;
  • litigated on behalf of The Dow Chemical Company up to the Supreme Court of the Netherlands against Organik Kimya on the seizure and inspection of evidence in a breach of trade secrets and on the safeguarding of confidentiality